ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Elecsys CSF AD immunoassays: Sample stability for a new pre-analytical protocol for fresh CSF.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Stage-dependent associations of plasma clusterin with reduced brain volume, tau pathology, and cognitive impairment across the Alzheimer's disease spectrum.Acta neurologica Belgica · 2026Article
- Elecsys CSF AD immunoassays: Sample stability for a new pre-analytical protocol for fresh CSF.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionAmyloid beta 1-42 (Aβ42), tau phosphorylated at threonine-181 (p-tau181), and total tau (t-tau) are cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease diagnosis.
methodsWe prospectively examined storage time, temperature, and freeze/thaw effects on Aβ42, p-tau181, and t-tau stability in fresh CSF samples using Elecsys
resultsAll three biomarkers were stable at 2-8°C for ≤15 days, and -25°C to -15°C for ≤8 weeks, and after one freeze/thaw cycle. p-Tau181 and t-tau were also stable at 15-25°C for ≤8 days and at -25°C to -15°C for 12-15 weeks. Aβ42 recovery declined slightly after storage at 15-25°C for ≤8 days and -25°C to -15°C for 12-15 weeks, and one freeze/thaw cycle. DISCUSSION: For optimal immunoassay performance, it is recommended to store CSF samples at 15-25°C for ≤5 days, 2-8°C for ≤15 days, and -25°C to -15°C for ≤8 weeks. HIGHLIGHTS: Cerebrospinal fluid (CSF) biomarkers aid in Alzheimer's disease diagnosis. Fresh CSF stored at 15-25°C for ≤5 days is optimal for Elecsys CSF immunoassays. Fresh CSF stored at 2-8°C for ≤15 days is optimal for Elecsys CSF immunoassays. Fresh CSF stored at -25°C to -15°C for ≤8 weeks is optimal for Elecsys CSF immunoassays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.